Corona examinations exceeded 8 million ... and 777 new infections were recorded
The UAE authorizes the emergency use of the "Covid-19" vaccine for members of the first line of defense
The vaccine was tried in 1,000 participants with chronic diseases, and no complications occurred.
■ archive
picture
The Minister of Health and Community Protection, Abdul Rahman bin Muhammad Al Owais, announced that the UAE has authorized the emergency use of the "Covid-19" vaccine to make it available to the groups most dealing with "Covid-19" sufferers from among the first line of defense heroes, with the aim of providing all safety means to these heroes and protecting them from any dangers They may be exposed to it due to the nature of their work.
He stressed that this emergency use of the vaccine is fully and completely in line with the regulations and laws that allow a faster review of licensing procedures.
This came during the periodic media briefing organized by the UAE government to address all developments related to the emerging corona virus, and ways to deal with it by the various work teams, as Al Owais confirmed that the Emirati leadership has taken an integrated set of wise decisions to deal with the emerging corona virus pandemic since the beginning of its spread. In the country, as all efforts were devoted to support the health sector system and provide it with everything it needs, and at the same time it was keen to adapt the scientific progress achieved to find effective and definitive solutions, which made the UAE a world leader in research and studies aimed at developing a safe and effective vaccine against 'Covid' -19 ».
He added that the spread of the pandemic around the world has caused great confusion to put health systems in a difficult test and challenge, as the greatest difficulty was in making crucial decisions that are able to enable the health care system to deal with the new reality, enhance its ability to control and contain the virus, reduce losses and preserve lives.
Al-Owais confirmed that the results of the studies during the final stages of the third phase showed that the vaccine is safe and effective and resulted in a strong response, and the generation of antibodies to the virus, as studies related to the safety of vaccination were reviewed, noting that this process is carried out under the strict supervision of a medical team to administer the study, and the health authorities By following all procedures to control the quality, safety and efficacy of the vaccine.
The Minister of Health and Community Protection stated that these steps are aimed at contributing to preserving the lives of millions of people and providing health care for the injured.
During the briefing, the spokesperson for the media briefing of the UAE government, Dr. Omar Al Hammadi, revealed the latest developments related to the case numbers, while the head of the National Clinical Committee for Coronavirus, the principal investigator for the third phase of clinical trials of the inactive COVID-19 vaccine, Dr. Nawal Al Kaabi, A complete summary of potential vaccine developments.
Al-Hammadi announced that the UAE is still at the forefront of countries around the world in the number of total examinations in relation to the population, bypassing the examinations barrier of eight million tests since the start of the pandemic.
It also announced the registration of 777 new cases of the disease, after 61,266 new examinations were conducted, bringing the total number of confirmed cases to 80,266 cases.
Al-Hammadi revealed that 530 recoveries were recorded, bringing the total number of recoveries to 69,981 cases, and no death was recorded during the past 24 hours, and based on previous data, the number of patients who are still receiving treatment is 9,886 cases.
Dr. Nawal Al-Kaabi revealed many developments about the third phase of clinical trials of the inactive vaccine to combat "Covid-19", confirming that the UAE is taking positive steps towards reaching the promising vaccine.
Al-Kaabi added that the country now includes a group of advanced facilities such as the "ADNEC Center", which is considered one of the largest field clinics for clinical trials, as 31,000 volunteers from 125 nationalities participated in these experiments.
Al-Kaabi indicated that simple and expected side effects, like any other vaccine, were observed, most of which were pain in the injection area, and a feeling of fatigue or simple headaches, while no serious side effects were recorded that require immediate treatment.
And she stressed that the initial results up to the present time are encouraging in terms of the presence of antibodies in the body, and the vaccine has been tried on 1000 volunteers suffering from chronic diseases and no complications occurred and the study is still ongoing.
She said that the vaccine will be provided optionally to individuals working on the first line of defense who are considered the most interacting with those infected with the Coronavirus, and the vaccine will also be available for specific groups optionally as well.
Emergency Use Criteria
The head of the National Clinical Committee for Coronavirus, Dr. Nawal Al-Kaabi, confirmed that the evaluation of the vaccine was based on the criteria for eligibility for approval for emergency use, which include a number of key elements, namely: A declaration by global health authorities of an emergency that leads to a serious or life-threatening disease or condition as it is. The case with the "Covid-19" pandemic, and the availability of scientific evidence proving the effectiveness of the product intended to face emergencies, the safety of its use, and the known and potential benefits of the product outweighing the known and potential risks, in addition to the manufacturer's request to authorize the vaccine.
She added that the evaluation was conducted with the emergency use license, taking into account the target groups, the characteristics of the product, the data of the clinical and preclinical study, the population study, and the collection of relevant scientific evidence available, stressing that the health authorities, in coordination with the implementing company, followed many measures to control the quality, safety and effectiveness of the vaccine, including : An emergency use of the product within a range determined by the legislative health authorities in the country, determining the number of target groups, the dose and the vaccination system, in addition to monitoring and reporting negative events.
Follow our latest local and sports news, and the latest political and economic developments via Google news